NBHC(NBHC)
NBHC
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $535M | $572M |
| Low | $531M | $569M |
| High | $537M | $575M |
| EBITDA Avg | $176M | $188M |
| Low | $175M | $187M |
| High | $177M | $189M |
| EBIT Avg | $153M | $164M |
| Low | $152M | $163M |
| High | $154M | $165M |
| Net Income Avg | $126M | $150M |
| Low | $124M | $147M |
| High | $128M | $153M |
| EPS Avg | $3.30 | $3.93 |
| Low | $3.24 | $3.85 |
| High | $3.35 | $4.00 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $136M | $139M | $139M | $143M | $144M | $147M |
| Low | $136M | $139M | $138M | $142M | $144M | $146M |
| High | $137M | $140M | $139M | $143M | $145M | $147M |
| EBITDA Avg | $45M | $46M | $46M | $47M | $47M | $48M |
| Low | $45M | $46M | $45M | $47M | $47M | $48M |
| High | $45M | $46M | $46M | $47M | $48M | $48M |
| EBIT Avg | $39M | $40M | $40M | $41M | $41M | $42M |
| Low | $39M | $40M | $40M | $41M | $41M | $42M |
| High | $39M | $40M | $40M | $41M | $41M | $42M |
| Net Income Avg | $32M | $36M | $36M | $38M | $38M | $39M |
| Low | $31M | $36M | $36M | $37M | $38M | $39M |
| High | $33M | $37M | $36M | $38M | $38M | $39M |
| EPS Avg | $0.83 | $0.95 | $0.94 | $0.98 | $0.99 | $1.01 |
| Low | $0.81 | $0.95 | $0.93 | $0.98 | $0.99 | $1.01 |
| High | $0.85 | $0.96 | $0.94 | $0.99 | $1.00 | $1.02 |
| Analysts (Rev / EPS) | 2 / 3 | 2 / 2 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |